TIVICAY, TRIUMEQ, and JULUCA recall in Canada: Neural tube defect risk
In plain language
This recall involves TIVICAY, TRIUMEQ, and JULUCA medications sold in Canada. They are being recalled because early findings suggest a possible increased risk of neural tube defects in infants born to women using these medications at the time of conception. Patients should not stop taking these medications without first talking to their healthcare professional.
What to do
- Stop using the product immediately.
- Consult your healthcare professional before making any changes to your medication.
- Discuss treatment options with your doctor if you are a woman of childbearing potential.
Get alerts for recalls like this
Get email alerts when new recalls affect products in this category.
Affected products
TIVICAY (dolutegravir)
TRIUMEQ (dolutegravir, abacavir, lamivudine)
JULUCA (dolutegravir, rilpivirine)
Why this matters
Risk of neural tube defects in infants
Do I have this product?
This recall only applies to specific products. Follow the steps below to check.
- 1
Check the product name
Make sure your product name matches one of the affected products listed above.
If your product matches one or more of the details above, it may be affected by this recall.
If your product does not match these details, it is not affected by this recall.
When in doubt, always check the official notice.
Frequently Asked Questions
Why was this product recalled?
Risk of neural tube defects in infants
What should consumers do?
Stop using the product immediately. Consult your healthcare professional before making any changes to your medication. Discuss treatment options with your doctor if you are a woman of childbearing potential.
Where was the product sold?
This product was sold in Canada. For specific retailers or distribution areas, please check the official recall notice linked on this page.
Is there a health risk?
Yes, there may be a health risk. Risk of neural tube defects in infants
When was this product recalled?
This product was recalled on June 7, 2018.